CABA Cabaletta Bio

Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference

Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference

PHILADELPHIA, May 29, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 11:05 a.m. ET in New York, NY.

A live webcast of the presentation will be available on the News and Events section of the Company’s website at . Replays will be available on the website for 30 days.

About Cabaletta Bio

Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases. The CABA™ platform encompasses two complementary strategies which aim to advance the discovery and development of engineered T cell therapies with the potential to become deep and durable, perhaps curative, treatments for a broad range of autoimmune diseases. The lead CARTA (Chimeric Antigen Receptor T cells for Autoimmunity) strategy is prioritizing the development of rese-cel, a 4-1BB-containing fully human CD19-CAR T cell investigational therapy. Rese-cel is currently being evaluated in the RESET™ (REstoring SElf-Tolerance) clinical development program spanning multiple therapeutic areas, including rheumatology, neurology and dermatology. Cabaletta Bio’s headquarters and labs are located in Philadelphia, PA. For more information, please visit  and connect with us on LinkedIn.

Contacts:



Anup Marda

Chief Financial Officer



EN
29/05/2025

Underlying

CABACabaletta Bio

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cabaletta Bio

 PRESS RELEASE
Free
CABA CABALETTA BIO

Cabaletta Bio Announces Pricing of Public Offering of Securities

Cabaletta Bio Announces Pricing of Public Offering of Securities PHILADELPHIA, June 11, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, announced today the pricing of an underwritten public offering consisting of (i) 39,200,000 shares of its common stock and accompanying warrants to purchase an aggregate of 39,200,000 shares of common stock (or pre-funded warrants in li...

June 11, 2025 1 EN
 PRESS RELEASE
Free
CABA CABALETTA BIO

Cabaletta Bio Announces Proposed Public Offering of Securities

Cabaletta Bio Announces Proposed Public Offering of Securities PHILADELPHIA, June 11, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, announced that it has commenced an underwritten public offering of shares of its common stock and accompanying warrants to purchase shares of its common stock (or pre-funded warrants in lieu thereof) and, in lieu of common stock, to certa...

June 11, 2025 1 EN
 PRESS RELEASE
Free
CABA CABALETTA BIO

Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patie...

Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress – 7 of 8 myositis patients achieved clinically meaningful TIS responses after discontinuation of all immunomodulators, while off or actively tapering steroids; responses were sustained throughout the follow-up period in all responding patients – – All SLE patients without nephropathy achieved definition of remission in SLE (DORIS) as of the latest follow-up, and all 7 SLE and LN patients experienced SLEDAI-2K reductions, while off all imm...

June 11, 2025 1 EN
 PRESS RELEASE
Free
CABA CABALETTA BIO

Cabaletta Bio to Participate in the Jefferies Global Healthcare Confer...

Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference PHILADELPHIA, May 29, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 11:05 a.m. ET in New York, NY. A live webcast of the presentation will be available on the News and Events sect...

May 29, 2025 1 EN
 PRESS RELEASE
Free
CABA CABALETTA BIO

Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in My...

Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent FDA Alignment on Registrational Cohorts        – Two subtype specific cohorts with ~15 patients each added to the ongoing RESET-Myositis™ trial – – RMAT designation granted for rese-cel in myositis, which is a disabling, multi-system autoimmune disease affecting approximately 80,000 U.S. patients with no approved treatments other than monthly IVIg – – Multiple Phase 1/2 disease cohorts fully enrolled across the RESET™ clinical development program; 44 patients enrolled and 23 patients dosed as of...

May 15, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch